Author:
Squadroni Michela,Barile Rosalba,Beretta Giordano
Publisher
Springer International Publishing
Reference48 articles.
1. Lloyd RVOR, et al. WHO classification of tumours of endocrine organs (World Health Organization classification of tumors). 4th ed. IARC Press; 2017.
2. Sørbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, Dueland S, Hofsli E, Guren MG, Ohrling K, Birkemeyer E, Thiis-Evensen E, Biagini M, Gronbaek H, Soveru LM, Olsen IH, Federspiel B, Assmus J, Janson ET, Knigge U. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3); the NORDIC NEC study. Ann Oncol. 2013;24(1):152–60.
3. Milione M, Maisonneuve P, Spada F, Pellegrinelli A, SPaggiari P, Albarello L, Pisa E, Barberis M, Vanoli A, Buzzoni R, Pusceddu S, Concas L, Sessa F, Solcia E, Capella C, Fazio N, La Rosa S. The clinicopathologic heterogeneity of Grade 3 gastroenteropancreatic neuroendocrine neoplasms: morphological differentiation and proliferation identify different prognostic categories. Neuroendocrinology. 2017;104(1):85–93.
4. Tang LH, Basturk O, Sue JJ, Klimstra DS. A practical approach to the classification of WHO Grade 3 (G3) well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas. Am J Surg Pathol. 2016;40(9):1192–202.
5. Travis W, Brambilla E, Burke A, et al. WHO classification of tumours of the lung, pleura, thymus and heart (World Health Organization classification of tumours). 4th ed. IARC Press; 2015.